Saturday, August 15, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
CRYPTOSEC Delays Crypto Rules—Uncertainty PersiststodayWHITE HOUSEWhite House 'Gold Eagle' AI Cyber Clearinghouse Is a Direct Revenue Signal for CrowdStrike and Palantir4 weeks agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff RefundtodayDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Hand a Direct Win to Directed-Energy Specialists4 weeks agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. MakerstodayHEALTHCARE & FDACMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM Rivals4 weeks agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis WinsyesterdayWHITE HOUSETrump Shrinks Two Utah Monuments by 90%, Opening Land to Mining and Drilling4 weeks agoDEFENSEBlackSky Lands Multi-Year Satellite ContractyesterdayENERGYTrump's Nuclear Push Is Driving a Real Uranium Mining Revival — These Are the Stocks That Collect4 weeks agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility2 days agoDEFENSEJohnson's $95 Billion Defense Spending Plan Has Lockheed, RTX, and Northrop Written All Over It4 weeks agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract2 days agoTRADE & TARIFFSPepsiCo's Tariff Refund Is a Small Win, But It Points to a Broader Cost Relief Story for Consumer Staples4 weeks agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock3 days agoENERGYNew Mexico Blocks Oracle's Data Center Gas Pipeline, Exposing the Fragility of Big Tech's Power Build-Out4 weeks agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask3 days agoDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Open a New Revenue Line for Northrop and L3Harris4 weeks agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance3 days agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee-War Warning Shot for Bitwise and Grayscale4 weeks agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing3 days agoTECHBosch's $225M CHIPS Award for Silicon Carbide Puts Wolfspeed and Onsemi on Notice4 weeks agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift4 days agoENERGYMichigan Renews Enbridge's Line 5 Tunnel Permit, Removing the Biggest Regulatory Overhang on the Stock4 weeks agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains5 days agoENERGYMichigan's Line 5 Permit Renewal Is a Clear Win for Enbridge — and a Setback for Pipeline Opponents4 weeks agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty5 days agoHEALTHCARE & FDACMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals4 weeks agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio6 days agoWHITE HOUSEWhite House Cybersecurity Clearinghouse Creates a Direct Revenue Line for CrowdStrike, Palantir, and Microsoft4 weeks agoDEFENSEPentagon Awards Space-Based Target Tracking Contracts6 days agoCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee Story — and a Pressure Test for Bitwise and Grayscale4 weeks agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes6 days agoWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes the Pecking Order — Microsoft and Oracle Gain, Open-Source Loses4 weeks agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employerslast weekHEALTHCARE & FDACMS's Site-Neutral and 340B Reform Proposal Squeezes Hospital Margins and Lifts Independent Pharmacies4 weeks agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backinglast weekTECHBosch's $225M CHIPS Award for Silicon Carbide Chips Is a Direct Threat to Wolfspeed's U.S. Market Share4 weeks agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payoutlast weekDEFENSEU.S.-Iran Escalation and a Stalled Strait of Hormuz Are a Windfall for Tanker Owners and Defense Primes4 weeks agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanomalast weekWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes Who Wins the Model Race4 weeks agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practiceslast weekENERGYNew Mexico's Pipeline Denial Puts Oracle's Data Center Expansion on Ice — and Highlights Every Hyperscaler's Power Risk4 weeks agoMARKETSFTC Threatens Booking Holdings Over Priceline Practiceslast weekENERGYNew Jersey's Nuclear Energy Law Opens a Real Revenue Path for Small Reactor Developers4 weeks agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlooklast weekDEFENSEPentagon's $80M Drone Defense Contract Points to the Counter-UAS Names Worth Watching4 weeks agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestonelast weekDEFENSEU.S.-Iran Conflict Escalation Stalls Hormuz Shipping — Defense Contractors and Oil Majors Are the Immediate Read4 weeks agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relieflast weekWHITE HOUSETrump's Defense Supply Chain Order Tightens Waiver Rules — Domestic Parts Makers Win, Foreign-Sourced Primes Face Friction4 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressurelast weekHEALTHCARE & FDACMS Freezes $1 Billion in Medicaid Payments to California and Minnesota — Managed Care Insurers Face Revenue Gaps3 weeks agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Winlast weekTECHBosch's $225M CHIPS Act Award for Roseville Chips Away at U.S. Dependence on Asian Auto Semiconductors3 weeks agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeezelast weekENERGYTrump's Saudi Nuclear Pact Without Enrichment Safeguards Heads to Congress — U.S. Uranium and Nuclear Services Names Are the Play3 weeks agoENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risklast weekWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Defense Supply Chain — and Sends Money to U.S. Miners3 weeks agoHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruptionlast weekCRYPTOWhite House Concedes Ethics Provision in Crypto Bill — Clearing the Last Roadblock for Stablecoin Legislation3 weeks agoWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Marketlast weekDEFENSEHouse Passes $1.15T Defense Bill — Missile Defense, Shipbuilding, and Next-Gen Air Get the Money3 weeks agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenuelast weekTRADE & TARIFFSTrump's 50% Canada Tariff Threat Keeps U.S. Aluminum Tight — Domestic Producers Win, Manufacturers Pay3 weeks agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Winlast weekENERGYNRC Approves Holtec's Upgraded Spent Fuel Storage System — A Quiet Win for Nuclear's Capacity Expansion3 weeks agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing2 weeks agoDEFENSEOracle Lands a $7B Pentagon Software Contract — and the Market Should Take It Seriously3 weeks agoTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall2 weeks agoDEFENSEThe U.S.-Iran War Is Costing $37.5B and Counting — Here's Where That Money Goes3 weeks agoSEARCH DEMANDData Center Power Exchange2 weeks agoENERGYTrump Signs the Saudi Nuclear Deal — and U.S. Uranium and Reactor Companies Are the Quiet Winners3 weeks agoSEARCH DEMANDCasgevy List Price: $2.2 Million2 weeks agoWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Military Supply Chain — These Miners Fill the Gap3 weeks agoENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors2 weeks agoCRYPTOThe Senate's Landmark Crypto Bill Creates Winners Inside the ETF and Exchange Stack3 weeks agoMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue2 weeks agoTRADE & TARIFFSTariffs on Indian Pharma Are Coming — and U.S. Generic Drug Buyers Will Pay the Bill3 weeks agoDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue2 weeks agoHEALTHCARE & FDACMS's Star Ratings Overhaul Rescues the Biggest Medicare Advantage Insurers — For Now3 weeks agoDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue2 weeks agoMARKETSChina's $765M Antitrust Fine on Trip.com Is a Warning Shot for U.S.-Listed Chinese Consumer Stocks3 weeks agoHEALTHCARE & FDACMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem2 weeks agoDEFENSEPentagon's $7B Oracle Software Deal Is One of the Cleanest Defense-Tech Wins in Years3 weeks agoCRYPTOSEC Settles Coinbase FOIA Suit Over Missing Gensler Texts—Crypto Compliance Pressure Eases, Coinbase Stock Gains Clarity2 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Direct Win for Oracle, Pressure on Smaller Defense IT Rivals3 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Cloud Incumbents Face Pressure, Oracle Locks in Defense Revenue2 weeks agoTECHFCC Tightens Submarine Cable Licensing Rules—Tech Giants Face New Compliance Costs, Telecom Carriers Gain Regulatory Clarity3 weeks agoDEFENSERocket Lab Wins $266M Space Force Missile Defense Contract—Suborbital Launch Niche Gets Federal Validation2 weeks agoHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—UnitedHealth, Humana, and Anthem Positioned to Gain from Simplified Metrics3 weeks agoHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten3 weeks agoDEFENSEHouse Passes $1.15 Trillion Defense Bill—Lockheed, Raytheon, and General Dynamics Positioned for Record Spending3 weeks agoDEFENSERocket Lab Wins $266M Space Force Contract—Suborbital Launch Capability Becomes Defense Asset3 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Largest Defense IT Overhaul in Years3 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare

GLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo

A CMS rule forcing Medicare and Medicaid to cover obesity drugs isn't a health story — it's a guaranteed revenue pipeline to two pharma giants, with insurers stuck footing the bill.

Image: Money Racket
By at Money Racket · Jun 3, 2026

Washington's GLP-1 moment is here. The Centers for Medicare and Medicaid Services has been under sustained pressure — through rulemaking, executive action, and congressional legislation — to classify obesity as a treatable condition under federal benefit programs, unlocking coverage for glucagon-like peptide-1 receptor agonists. For decades, Medicare Part D was statutorily barred from covering drugs used solely for "weight loss." Any CMS rule or legislative fix breaking that wall doesn't just change health policy. It opens a federally guaranteed buyer for the two most expensive drug classes in modern medicine.

The mechanism is straightforward: CMS sets coverage rules, and formulary access follows. Approximately 67 million Americans are enrolled in Medicare; another 92 million in Medicaid. Even a modest penetration rate of eligible obese beneficiaries at current list prices — Zepbound and Wegovy each run above $10,000 per patient annually before rebates — produces a revenue step-change that no commercial market expansion can match.

Every percentage point of Medicare penetration translates to billions in net revenue — and Washington, not the market, is pulling the trigger.

Who cashes in

LLY (Eli Lilly) is the most direct beneficiary. Zepbound (tirzepatide) holds FDA approval for chronic weight management and is already generating blockbuster commercial revenue. Federal coverage is the missing volume lever — it routes tens of millions of price-insensitive, government-backed prescriptions toward a product Lilly is actively scaling manufacturing to supply. Every percentage point of Medicare penetration translates to billions in net revenue.

NVO (Novo Nordisk) owns the second major position through Wegovy (semaglutide), which also carries FDA cardiovascular risk-reduction labeling — a clinical hook that makes coverage denial legally harder. Novo's established formulary relationships and rebate infrastructure give it a fast lane once federal coverage opens.

CVS Health (CVS), through its Caremark PBM, manages pharmacy benefits for a large share of Medicare Part D plans. A coverage expansion drives prescription volume across its mail-order and specialty pharmacy network — a high-margin revenue stream — even as it simultaneously pressures the insurance side of its business.

Who is exposed

UNH (UnitedHealth Group) faces the sharpest near-term pressure. As the largest Medicare Advantage insurer, UnitedHealth absorbs drug spend that federal per-capita rates may not fully reimburse. GLP-1s at scale could compress medical loss ratios before CMS benchmarks adjust — a timing mismatch that has historically punished MA plan economics.

CVS is also on the exposed list in its Aetna insurance division, for the same reason: higher pharmacy spend with plan premium adjustments lagging by a full contract cycle.

What to watch

Track CMS proposed rulemaking under the Medicare Prescription Drug, Improvement, and Modernization Act, and any legislative language in reconciliation vehicles that explicitly includes obesity drugs in Part D's covered categories. The CBO score on federal coverage cost will be the tell — the higher the estimate, the more real the market is pricing in.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/glp1-medicare-medicaid-coverage-mandate-lilly-novo-windfall/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →